

New Targeted Therapies for Improving Cholesterol and CV Outcomes in Patients with
FAMILIAL HYPERCHOLESTEROLEMIA

THE VIRTUAL REALITY ROOM



FACULTY

Robert S. Rosenson, MD

Professor of Medicine (Cardiology), Icahn School of
Medicine at Mount Sinai

Director of Metabolism and Lipids, Mount Sinai Health System
Icahn School of Medicine at Mount Sinai
New York, NY

PROGRAM DESCRIPTION

This Virtual Reality Room invites learners to experience a virtual world illustrating the identification, diagnosis, and treatment of familial hypercholesterolemia (FH). Through this sensory-immersive experience, a series of virtual reality animations will also allow learners to explore the genetic underpinnings of FH, variants in the development of FH, pathways implicated in the disease (LDL-receptor dependent and independent) as well as mechanisms of action for current and emerging therapies for patients with this difficult-to-treat condition.

LEARNING OBJECTIVES

- Develop tailored, intensified, lipid-lowering regimens based on clinical guidance, individual patient risk factors, comorbidities, and prior treatment for patients with FH
- Interpret evidence from clinical trials assessing therapies for the treatment of patients with FH, including long-term cardiovascular outcomes
- Prepare treatment plans that account for genetic aberrations impacting the activity of low-density-lipoprotein receptors in patients with FH